<DOC>
	<DOCNO>NCT00189579</DOCNO>
	<brief_summary>The purpose study evaluate whether addition Herceptin may benefit standard regimen carboplatin-paclitaxel .</brief_summary>
	<brief_title>Addition Herceptin Carboplatin-Paclitaxel Regimen Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>18 year old ; patient histologically proven diagnosis ovarian cancer . Patients metastatic disease overexpression HER2 ( determined immunochemistry ) Patients progress receive treatment , within 6 month completion treatment . Patients must receive carboplatin paclitaxel . Patients receive minimum one line chemotherapy 3 week minimum since last treatment chemotherapy must elapse Patients must least 1 measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) assessable cancer antigen ( CA ) 125 &gt; 1.25 x upper limit normal ( ULN ) Patients must ECOG 2 less Left ventricular ejection fraction ( LVEF ) 50 % good Patients give sign verbal consent Previous treatment Herceptin similar product affect growth factor ( eg : Iressa ) Another experimental treatment previous 30 day No overexpression HER2 receptors Patients receive highdose chemotherapy stemcell intervention Other cancer within last 5 year Patients dyspnea rest require oxygen therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HERCEPTIN</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Relapse</keyword>
</DOC>